Semaglutide Guide: The Complete GLP-1 Reference

Summary: Semaglutide is a once-weekly GLP-1 receptor agonist sold as Ozempic, Wegovy, and Rybelsus that lowers A1C, drives roughly 15% weight loss in STEP-1, and cuts cardiovascular events in SELECT.

This content is for informational purposes only and is not medical advice. Always consult a qualified healthcare provider before starting, changing, or stopping any medication.

Semaglutide is a once-weekly GLP-1 receptor agonist developed by Novo Nordisk and sold under three brand names: Ozempic for type 2 diabetes, Wegovy for chronic weight management, and Rybelsus as a daily oral tablet for diabetes. All three contain the same molecule. The dose, the indication, and the device differ. This is the canonical reference for what semaglutide is, how it works, what the trial data actually shows, and how the four FDA-approved products differ from each other.

What semaglutide actually is

Semaglutide is a synthetic analog of glucagon-like peptide-1, a gut hormone your body releases after meals. The native hormone has a half-life of about two minutes because an enzyme called DPP-4 chews it apart. Novo Nordisk's chemists modified the peptide backbone at two positions and attached a fatty acid chain, which lets the molecule bind to albumin in the blood and survive for roughly a week. That is why semaglutide is dosed weekly while the body's own GLP-1 lasts only minutes ^[1].

The drug is a peptide, not a small molecule and not a biologic in the antibody sense. It does not contain mRNA. It is not derived from Gila monster venom; that distinction belongs to exenatide, an older GLP-1 mimetic based on a peptide called exendin-4 found in Gila monster saliva. Semaglutide is fully synthetic and structurally closer to human GLP-1 than exenatide is.

The brand names and what each one is for

Four products on the US market contain semaglutide as of 2026.

Ozempic was the first to launch, approved by the FDA in December 2017 for adults with type 2 diabetes ^[1]. Rybelsus followed in September 2019 as the first oral GLP-1 in any class. Wegovy injection arrived in June 2021 for adults with obesity or overweight plus a weight-related condition, and the FDA extended the label to adolescents 12 and older in December 2022. Novo Nordisk's oral semaglutide for weight loss received FDA approval in 2025 at the 25 mg daily tablet dose, making it the first oral GLP-1 cleared for chronic weight management.

The active ingredient is identical across all four. What changes is the maximum dose (Wegovy goes higher than Ozempic), the route (injection versus oral), and the label (diabetes versus obesity). Insurance will cover one and not the other depending on your diagnosis, which is the practical reason the same molecule has four different names.

How semaglutide works

Semaglutide activates the GLP-1 receptor on multiple cell types. Three effects do most of the clinical work.

In the pancreas, it boosts insulin release in response to elevated blood glucose and suppresses glucagon. The "glucose-dependent" part matters. Unlike sulfonylureas, semaglutide does not push insulin when glucose is normal, so the hypoglycemia risk is low when used as monotherapy.

In the stomach, it slows gastric emptying. Food sits longer, glucose absorption is more gradual, and you feel full earlier and for longer. This is the mechanism behind the most common side effects (nausea, early satiety, occasional vomiting) and behind most of the appetite suppression people describe.

In the brain, semaglutide acts on GLP-1 receptors in the hypothalamus and hindbrain to dial down hunger signals and reduce food reward. People in the STEP trials reported lower cravings, fewer thoughts about food, and easier portion control at higher doses ^[3]. That central effect is why the weight loss continues past the point where slowed gastric emptying alone would explain it.

The combined result: better glycemic control in diabetes, meaningful weight loss in obesity, and downstream improvements in blood pressure, triglycerides, and inflammatory markers that look a lot like what cardiologists and nephrologists hoped for.

A short history of the molecule

Semaglutide is the third major GLP-1 receptor agonist Novo Nordisk brought to market, following liraglutide (Victoza, 2010; Saxenda, 2014). The molecule was developed in the early 2010s through a deliberate engineering exercise: take liraglutide's albumin-binding strategy, refine the substitutions, and stretch the half-life from one day to one week.

The pivotal diabetes program was the SUSTAIN series, six trials enrolling roughly 7,000 people with type 2 diabetes across various comparators. SUSTAIN-6, published in NEJM in 2016, was the cardiovascular outcomes trial that the FDA had required for every new diabetes drug since 2008. Semaglutide reduced the rate of major adverse cardiovascular events by 26% over two years in people with established cardiovascular disease, which set up the December 2017 approval ^[1].

The obesity program was STEP, eight trials enrolling roughly 4,500 adults with obesity. STEP-1, the foundational placebo-controlled trial in adults without diabetes, ran 68 weeks at the 2.4 mg weekly dose and reported a mean weight change of -14.9% in the semaglutide group versus -2.4% with placebo ^[3]. That single number, "about 15% weight loss," is what drove the cultural moment Wegovy created starting in 2021.

SELECT followed in 2023. Roughly 17,600 adults with overweight or obesity and pre-existing cardiovascular disease, but without diabetes, took 2.4 mg semaglutide or placebo for a median of 40 months. The primary endpoint of cardiovascular death, nonfatal myocardial infarction, or nonfatal stroke fell by 20% (hazard ratio 0.80) ^[4]. The FDA added a cardiovascular risk reduction indication to the Wegovy label in March 2024, making semaglutide the first weight-loss drug with that kind of outcome data.

FLOW, published in 2024, looked at kidney protection. About 3,500 adults with type 2 diabetes and chronic kidney disease took 1.0 mg semaglutide or placebo. The trial was stopped early for benefit. Major kidney disease events fell by 24%, and all-cause death dropped by 20% ^[5]. The kidney indication is now part of the Ozempic label conversation, and it strengthens the case that semaglutide's value extends well past glycemic control.

Dosing across the four products

Every product titrates. Starting at the maintenance dose causes intolerable nausea in most people, so Novo Nordisk built four-week steps into every label. The Ozempic schedule is 0.25 mg for four weeks, 0.5 mg for at least four weeks, optional 1.0 mg, optional 2.0 mg ^[1]. The Wegovy injection schedule climbs through 0.25, 0.5, 1.0, 1.7, and 2.4 mg over 16 to 20 weeks ^[2]. Skipping steps almost always backfires.

Rybelsus has a quirk that catches new patients. The tablet must be swallowed whole with no more than four ounces of plain water, at least 30 minutes before any food, drink, or other oral medication. That fasting window is what gets the peptide across the gut wall intact. Take it with breakfast and absorption drops to near zero.

Efficacy: what the numbers actually look like

For type 2 diabetes, the SUSTAIN trials reported A1C reductions of roughly 1.4 to 1.8 percentage points at the 1.0 mg dose over 30 to 56 weeks, with the 2.0 mg dose adding another 0.2 to 0.3 points. Most people taking 1.0 mg semaglutide drop their A1C below the 7.0% target that ADA guidelines flag as the threshold for good control. Fasting glucose typically falls 30 to 50 mg/dL. Weight loss in diabetes patients runs about 4 to 6 kg, smaller than in obesity trials because the dose is lower and because diabetes physiology makes weight loss harder.

For weight loss in adults without diabetes, STEP-1 set the headline number at -14.9% mean weight change at 68 weeks on 2.4 mg ^[3]. About a third of participants lost at least 20% of their starting weight. Waist circumference dropped roughly 13 cm. Systolic blood pressure fell about 6 mmHg. Triglycerides, LDL, and inflammatory markers all moved in the right direction.

For cardiovascular event prevention, SELECT's 20% relative risk reduction in MACE translates to roughly one prevented cardiovascular event for every 67 people treated for nearly three years ^[4]. That number-needed-to-treat puts semaglutide in the same conversation as statins for secondary prevention.

For kidney protection, FLOW reported a 24% relative reduction in major kidney disease events, defined as a composite of substantial GFR decline, kidney failure, or kidney-related death ^[5]. The same trial showed a 29% reduction in cardiovascular death and a 20% drop in all-cause mortality. Stopping a trial early for benefit is rare; FLOW did it.

Side effects, in honest terms

About 70 to 80% of people on semaglutide experience some gastrointestinal side effect during titration. Nausea is the most common, followed by diarrhea, constipation, vomiting, and abdominal pain. Most of it appears in the first eight weeks, peaks around the dose-step weeks, and fades as the body adapts. About 5 to 7% of people in trials discontinued treatment because of GI effects ^[3].

Less common but more serious risks listed in the prescribing information:

• Pancreatitis. Acute pancreatitis was reported at a low absolute rate in trials but at a slightly higher rate than placebo. Severe persistent abdominal pain that radiates to the back is the warning sign that needs urgent evaluation.
• Gallbladder disease. Rapid weight loss raises gallstone risk; semaglutide contributes via that pathway and possibly via direct effects on bile flow.
• Diabetic retinopathy progression in type 2 diabetes. SUSTAIN-6 flagged a small increase in retinopathy complications, most likely tied to the speed of A1C drop in people with pre-existing eye disease.
• Thyroid C-cell tumors. Rodent studies showed dose-dependent thyroid C-cell tumors, which is why every GLP-1 label carries a boxed warning against use in people with personal or family history of medullary thyroid carcinoma or MEN 2 ^[1][2].
• Acute kidney injury, almost always secondary to dehydration from vomiting or diarrhea. Hydrate aggressively if you cannot keep fluids down.
• Hypoglycemia is uncommon as monotherapy. Risk rises sharply when combined with insulin or sulfonylureas, which usually need dose reductions.

Gastroparesis is the side effect that captured the most press in 2023 and 2024. Slowed gastric emptying is the mechanism, not the side effect; the question is whether semaglutide causes clinically significant gastroparesis that persists. Case reports exist. The trial data show the rate is low, probably under 1%, and most cases resolve when the drug is stopped. People with pre-existing severe gastroparesis should not start semaglutide.

Cost and access

The Ozempic and Wegovy list prices in the US sit around $1,000 per month before insurance. Cash prices through manufacturer programs and large pharmacy chains run $1,200 to $1,400 for a one-month supply of Wegovy, and around $1,000 for Ozempic. Insurance coverage varies wildly. Type 2 diabetes coverage is usually straightforward; weight-loss coverage is far harder, and most commercial plans either exclude obesity drugs entirely or require prior authorization, BMI documentation, and proof of prior diet and exercise attempts.

The 2022 to 2024 semaglutide shortage opened the door for compounding pharmacies, which produced large volumes of compounded semaglutide at prices between $200 and $400 per month. The FDA officially removed semaglutide from the shortage list in early 2025, which narrowed the legal pathway for compounding, but a meaningful gray market remains. Compounded semaglutide is the same active molecule on paper, but it is not FDA-approved, manufacturing oversight is lighter, and the concentration math depends on your pharmacy.

How semaglutide compares to other GLP-1 drugs

Semaglutide is the second-most-prescribed GLP-1 in the US. The first is tirzepatide (Mounjaro for diabetes, Zepbound for weight loss), which acts on both the GLP-1 receptor and the GIP receptor. Head-to-head data from SURMOUNT and SURPASS suggest tirzepatide produces somewhat larger weight loss at maximum doses (about 20 to 22%) than semaglutide does (about 15%). For glycemic control the gap is smaller. For cardiovascular outcomes, semaglutide has the larger evidence base because SELECT and SUSTAIN-6 are complete and tirzepatide's outcomes trial (SURPASS-CVOT) is still reading out.

Liraglutide (Victoza, Saxenda) is the older Novo Nordisk GLP-1 and the structural parent of semaglutide. It is dosed daily, produces smaller weight loss (about 5 to 8%), and is mostly being replaced by the weekly drugs.

Dulaglutide (Trulicity) is Lilly's older GLP-1, weekly, with smaller weight loss and similar diabetes efficacy to semaglutide 1.0 mg.

The choice between GLP-1s in 2026 mostly comes down to insurance coverage, the indication, and which side effects each person tolerates best. Switching between drugs in the class is common and clinically reasonable.

Common questions about semaglutide

Is semaglutide the same as Ozempic?

Yes. Ozempic is one brand of semaglutide. Wegovy and Rybelsus are the other two FDA-approved brands. The active ingredient is identical.

Is Ozempic a GLP-1?

Yes. Ozempic, Wegovy, and Rybelsus are all semaglutide, which is a GLP-1 receptor agonist. Other GLP-1 receptor agonists include liraglutide, dulaglutide, exenatide, and the dual GIP/GLP-1 drug tirzepatide.

Is semaglutide a peptide drug?

Yes. Semaglutide is a 31-amino-acid peptide modified at two positions and linked to a fatty acid chain, which is what gives it a one-week half-life.

Does Ozempic contain mRNA?

No. Semaglutide is a peptide synthesized in a controlled chemical process. There is no mRNA, no DNA, and no live or attenuated organism in the product.

Is Ozempic made from Gila monster venom?

No. Exenatide is the GLP-1 drug derived from Gila monster saliva. Semaglutide is fully synthetic and structurally closer to human GLP-1.

How long has semaglutide been studied?

Phase 2 trials started in the early 2010s. The first FDA approval (Ozempic) came in December 2017. Semaglutide has been on the US market for roughly eight years and has been studied in tens of thousands of patients across the SUSTAIN, STEP, SELECT, FLOW, and PIONEER trial programs.

What is the difference between Wegovy and Ozempic?

Same molecule, different dose ceiling and indication. Wegovy tops out at 2.4 mg weekly and is FDA-approved for chronic weight management. Ozempic tops out at 2.0 mg weekly and is approved for type 2 diabetes and cardiovascular risk reduction in diabetes.

What is Rybelsus?

Rybelsus is the daily oral tablet form of semaglutide, approved in 2019 for type 2 diabetes. It uses a permeation enhancer to get the peptide across the stomach lining. Doses are 3, 7, and 14 mg.

How much weight do people lose on semaglutide?

In the STEP-1 trial at 2.4 mg weekly for 68 weeks, mean weight change was -14.9% in the semaglutide group versus -2.4% on placebo. About one third of participants lost at least 20% of starting body weight.

Is buying semaglutide for weight loss online safe?

It depends on the source. Telehealth providers that prescribe brand Wegovy through licensed US pharmacies are operating legally. Sites that ship "research peptides" without a prescription are not, and the product quality varies. Compounded semaglutide from a licensed compounding pharmacy with a real prescription sits in between: legal in many cases, less regulated than brand-name product.

Can semaglutide be used for type 2 diabetes?

Yes. That was the original FDA indication in 2017. Ozempic at 0.5 to 2.0 mg weekly is one of the most prescribed type 2 diabetes drugs in the US.

How does semaglutide help you lose weight?

Three mechanisms: it slows gastric emptying so you feel full earlier, it acts on hunger centers in the brain to reduce appetite and food cravings, and it improves insulin and glucagon signaling. Together those effects reduce calorie intake by several hundred calories per day.

Where to read next

This page is the canonical semaglutide overview. Specific dosing tables, side-effect timelines, brand-by-brand cost breakdowns, and comparisons to tirzepatide live on their own dedicated pages on this site. The semaglutide dosage chart, semaglutide side effects, Ozempic versus Wegovy, and compounded semaglutide articles are the natural next stops.